Bioenvision to Present at CIBC World Markets Seventeenth Annual Healthcare Conference

  
    
  
  
    
      Bioenvision, Inc. (NasdaqGM:BIVN) announced today that Dr. Christopher 
      B. Wood, Chairman and Chief Executive Officer of the Company, will 
      present at the CIBC World Markets 17th Annual 
      Healthcare Conference on Tuesday, November 7, 2006 at 8:35am EST. The 
      event is being held at the Waldorf-Astoria in New York City.
    
    
      A live webcast of the presentation will be available at http://www.veracast.com/webcasts/cibcwm/healthcare06/35202217.cfm. 
      The webcast will be archived and the link will remain active through 
      February 8, 2007.
    
    
      About Bioenvision
    
    
      Bioenvision's primary focus is the acquisition, development, 
      distribution and marketing of compounds and technologies for the 
      treatment of cancer. Bioenvision has a broad pipeline of products for 
      the treatment of cancer, including: Evoltra®, 
      Modrenal® (for which Bioenvision has obtained 
      regulatory approval for marketing in the United Kingdom for the 
      treatment of post-menopausal breast cancer following relapse to initial 
      hormone therapy), and other products. Bioenvision is also developing 
      anti-infective technologies, including the OLIGON® 
      technology, an advanced biomaterial that has been incorporated into 
      various FDA approved medical devices and Suvus®, 
      an antimicrobial agent currently in clinical development for refractory 
      chronic hepatitis C infection. For more information on Bioenvision 
      please visit our Web site at www.bioenvision.com.
    
    
      Certain statements contained herein are "forward-looking" statements 
      (as such term is defined in the Private Securities Litigation Reform Act 
      of 1995). Because these statements include risks and uncertainties, 
      actual results may differ materially from those expressed or implied by 
      such forward-looking statements. Specifically, factors that could cause 
      actual results to differ materially from those expressed or implied by 
      such forward-looking statements include, but are not limited to: risks 
      associated with preclinical and clinical developments in the 
      biopharmaceutical industry in general and in Bioenvision's compounds 
      under development in particular; the potential failure of Bioenvision's 
      compounds under development to prove safe and effective for treatment of 
      disease; uncertainties inherent in the early stage of Bioenvision's 
      compounds under development; failure to successfully implement or 
      complete clinical trials; failure to receive marketing clearance from 
      regulatory agencies for our compounds under development; acquisitions, 
      divestitures, mergers, licenses or strategic initiatives that change 
      Bioenvision's business, structure or projections; the development of 
      competing products; uncertainties related to Bioenvision's dependence on 
      third parties and partners; and those risks described in Bioenvision's 
      filings with the SEC. Bioenvision disclaims any obligation to update 
      these forward-looking statements.
    
  
Bioenvision, Inc. (NasdaqGM:BIVN) announced today that Dr.
Christopher B. Wood, Chairman and Chief Executive Officer of the
Company, will present at the CIBC World Markets 17th Annual Healthcare
Conference on Tuesday, November 7, 2006 at 8:35am EST. The event is
being held at the Waldorf-Astoria in New York City.

   A live webcast of the presentation will be available at
http://www.veracast.com/webcasts/cibcwm/healthcare06/35202217.cfm. The
webcast will be archived and the link will remain active through
February 8, 2007.

   About Bioenvision

   Bioenvision's primary focus is the acquisition, development,
distribution and marketing of compounds and technologies for the
treatment of cancer. Bioenvision has a broad pipeline of products for
the treatment of cancer, including: Evoltra(R), Modrenal(R) (for which
Bioenvision has obtained regulatory approval for marketing in the
United Kingdom for the treatment of post-menopausal breast cancer
following relapse to initial hormone therapy), and other products.
Bioenvision is also developing anti-infective technologies, including
the OLIGON(R) technology, an advanced biomaterial that has been
incorporated into various FDA approved medical devices and Suvus(R),
an antimicrobial agent currently in clinical development for
refractory chronic hepatitis C infection. For more information on
Bioenvision please visit our Web site at www.bioenvision.com.

   Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Specifically,
factors that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements include,
but are not limited to: risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and in
Bioenvision's compounds under development in particular; the potential
failure of Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure to
successfully implement or complete clinical trials; failure to receive
marketing clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure or
projections; the development of competing products; uncertainties
related to Bioenvision's dependence on third parties and partners; and
those risks described in Bioenvision's filings with the SEC.
Bioenvision disclaims any obligation to update these forward-looking
statements.